EP Patent

EP4087625A4 — POLYMER COMPOSITIONS AND BIOSURFACES CONTAINING SAME ON SENSORS

Assigned to Zepto Life Technology Inc · Expires 2024-03-13 · 2y expired

What this patent protects

Patent listed against Balversa.

Drugs covered by this patent

Balversa (ERDAFITINIB) · Johnson & Johnson

Patent Metadata

Patent number: EP4087625A4
Jurisdiction: EP
Classification: —
Expires: 2024-03-13
Drug substance claim: No
Drug product claim: No
Assignee: Zepto Life Technology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.